Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL
Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL
Not yet recruiting · NCT06658925 · Registry updated 2024-10-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL | HSCT; Ph+ Acute Lymphoblastic Leukemia (Ph+ALL); Tyrosine Kinase Inhibitor | Not yet recruiting | Phase 2 | 2024-10-26 | NCT06658925 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 285 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||